Bionano Genomics Inc Cash Flow-to-Debt Ratio
Bionano Genomics Inc cash flow-to-debt ratio. Bionano Genomics Inc (BNGO) has a Cash Flow-to-Debt Ratio of -0.29x as of June 2026, meaning its operating cash flow of $-4.67 Million could theoretically repay 0% of its total liabilities ($15.98 Million) in one year. See how financially flexible is Bionano Genomics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Bionano Genomics Inc (2016–2025)
Cash flow-to-debt ratio of Bionano Genomics Inc from 2016 to 2025. Historical debt coverage capacity for Bionano Genomics Inc across 10 annual periods. Also explore BNGO net assets growth trend to track the company's year-over-year net asset growth rate.
Bionano Genomics Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Bionano Genomics Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Bionano Genomics Inc. For the full cash flow conversion analysis, see BNGO cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.56x | $-16.34 Million | $29.16 Million | ▲ +66.4% |
| 2024 | -1.67x | $-68.92 Million | $41.30 Million | ▼ -57.7% |
| 2023 | -1.06x | $-125.18 Million | $118.25 Million | ▲ +50.7% |
| 2022 | -2.15x | $-124.82 Million | $58.10 Million | ▼ -19.4% |
| 2021 | -1.80x | $-71.93 Million | $39.98 Million | ▼ -19.1% |
| 2020 | -1.51x | $-38.31 Million | $25.37 Million | ▼ -36.0% |
| 2019 | -1.11x | $-29.53 Million | $26.59 Million | ▲ +18.4% |
| 2018 | -1.36x | $-19.94 Million | $14.67 Million | ▼ -294.4% |
| 2017 | -0.34x | $-20.82 Million | $60.37 Million | ▲ +38.3% |
| 2016 | -0.56x | $-23.50 Million | $42.05 Million | — |